WO2017158152A1 - Diagnostic de la broncho-pneumopathie chronique obstructive (bpco) - Google Patents

Diagnostic de la broncho-pneumopathie chronique obstructive (bpco) Download PDF

Info

Publication number
WO2017158152A1
WO2017158152A1 PCT/EP2017/056362 EP2017056362W WO2017158152A1 WO 2017158152 A1 WO2017158152 A1 WO 2017158152A1 EP 2017056362 W EP2017056362 W EP 2017056362W WO 2017158152 A1 WO2017158152 A1 WO 2017158152A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
copd
level
fragments
subject
Prior art date
Application number
PCT/EP2017/056362
Other languages
English (en)
Inventor
Tilo Buschmann
Sabina CHRIST-BREULMANN
Maik FRIEDRICH
Jens HOHLFELD
Friedemann Horn
Norbert Krug
Kristin Reiche
Kai Sohn
Original Assignee
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. filed Critical Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.
Publication of WO2017158152A1 publication Critical patent/WO2017158152A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • COPD chronic obstructive pulmonary disease
  • the present invention is in the field of medicine, more in particular diagnostics and even more in particular the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD), a chronic airway inflammation associated with cough, sputum, and shortness of breath.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • COPD risk factors such as tobacco smoke
  • other organs are affected leading to comorbidities contributing to the morbidity and mortality of the disease.
  • COPD will rank third in global mortality by 2020.
  • COPD is a widespread disease that affects 600 million people worldwide. In Germany, nearly 15% of the over 40-year-old population suffer from COPD.
  • the prevalence and burden of COPD is projected to increase worldwide in the coming decades because of continued exposure to COPD risk factors and the changing age structure of the population due to increasing longevity.
  • COPD treatment is mainly symptomatic targeting the airway obstruction with short- and long-acting bronchodilators.
  • measurement of pulmonary function is the key outcome variable to monitor treatment responses.
  • Treatment regimens are based on disease severity with pulmonary function guiding the standard of care. While assessment of treatment responses by pulmonary function measurement is standard of care for bronchodilator therapy because it directly captures changes in airway physiology, the development of novel anti-inflammatory drugs is hampered due to the indirect connection of airway physiology with the underlying airway inflammation. While it is very well conceivable that anti-inflammatory treatments ultimately affect and improve airway function, it would be desirable to directly monitor treatment responses with a valid biomarker that indicates anti-inflammatory efficacy positively impacting on morbidity and mortality.
  • Measurement of pulmonary function is the current standard of care to monitor treatment responses in COPD. While treatment modalities with an acute onset of action such as bronchodilators can be directly assessed by measurement of pulmonary function, treatments that target the underlying airway inflammation also have to use the physiologic outcome measure due to lacking alternatives although their mode of action is not related to airway obstruction.
  • Novel (anti-inflammatory) treatments that claim to modify the disease course need to be developed in due time.
  • clinical trials that assess pulmonary function or the rate of exacerbations as the primary outcome are time- and cost-intensive. Therefore, there is a high medical need to develop novel biomarkers that are able to monitor treatment responses of disease-modifying investigational new drugs without the need for lengthy studies that capture the natural course of disease as the primary outcome.
  • the pharmaceutical industry (Glaxo SmithKline) has initiated and conducted a large longitudinal observation of a COPD cohort (ECLIPSE) with almost 3,000 subjects followed up for 3 years in order to identify novel biomarkers for treatment responses. Hitherto, no valid biomarker has been identified that has the potential to improve the decision making.
  • the present invention solves the above-mentioned problems, by providing for a method for the diagnosis of COPD, risk stratification, disease outcome, disease prognosis, or differential severity analysis of COPD in a subject that has or is suspected to have COPD, comprising the steps of, in a sample of said subject:
  • NO. 233 or fragments thereof is correlated with the diagnosis of COPD, a defined risk stratification, a defined disease outcome, a defined disease prognosis, or a differential severity of COPD in a subject,
  • diagnosis of COPD, defined risk stratification, defined disease outcome, defined disease prognosis, or a differential severity of COPD in a subject is given if the level of one or more transcripts according to SEQ ID NO. 75 to SEQ ID NO. 233 or fragments thereof is above or below a certain cut-off value.
  • the invention relates to biomarkers which are either significantly up- or down regulated.
  • the invention also relates to a primer or probe nucleic acid or equivalent thereto that hybridizes under stringent conditions to a transcript or fragment of a a nucleic acid transcript with a SEQ ID NO. 75 to SEQ ID NO. 233. It relates to uses and kits. This is the first ever COPD biomarker which allows for diagnosis, differential diagnosis and severity analysis and risk stratification.
  • the terms “threshold”, “threshold value”, “cut-off” and “cut-off value” are used synonymously.
  • the biomarkers herein are either up- or downregulated versus this cut-off value.
  • the term “correlating,” as used herein in reference to the use of diagnostic and prognostic markers, refers to comparing the presence or amount of the marker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. As discussed above, a marker level in a patient sample can be compared to a level known to be associated with a specific diagnosis.
  • the sample's marker level is said to have been correlated with a diagnosis; that is, the skilled artisan can use the marker level to determine whether the patient suffers from a specific type diagnosis, and respond accordingly.
  • the sample's marker level can be compared to a marker level known to be associated with a good outcome (e.g., the absence of disease, etc.).
  • a profile of marker levels is correlated to a global probability or a particular outcome.
  • nucleic acid(s) or “nucleic acid molecule” generally refers to any ribonucleic acid or deoxyribonucleic acid, which may be unmodified or modified.
  • Nucleic acids include, without limitation, single- and double-stranded nucleic acids.
  • nucleic acid(s) also includes nucleic acids as described above that contain one or more modified bases. Thus, a nucleic acid with one or several backbone modifications for stability or for other reasons is a "nucleic acid”.
  • nucleic acids encompasses such chemically, enzymatically or metabolically modified forms of nucleic acids, as well as the chemical forms of nucleic acids characteristic of viruses and cells, including for example, simple and complex cells.
  • the transcripts referred to herein are nucleic acids.
  • a “prognosis” refers to assignment of a probability that a given course or outcome will occur. This is often determined by examining one or more "prognostic indicators". These are markers, the presence or amount of which in a patient (or a sample obtained from the patient) signal a probability that a given course or outcome will occur. For example, when one or more prognostic indicators reach a sufficiently high level in samples obtained from such patients, the level may signal that the patient is at an increased probability for eventually advancing into a higher GOLD stage of FEVi. There are a number of methods to determine how much COPD is affecting a given individual. The modified British Medical Research Council questionnaire (mMRC) or the COPD assessment test (CAT) are simple questionnaires that may be used to determine the severity of symptoms.
  • mMRC British Medical Research Council questionnaire
  • CAT COPD assessment test
  • Scores on CAT range from 0-40 with the higher the score, the more severe the disease. Spirometry may help to determine the severity of airflow limitation. This is typically based on the FEVi expressed as a percentage of the predicted "normal" for the person's age, gender, height and weight. Both the American and European guidelines recommended partly basing treatment recommendations on the FEVi. The GOLD guidelines suggest dividing people into four categories based on symptoms assessment and airflow limitation.
  • level or "expression level” in the context of the present invention relate to the level at which a biomarker is present in a sample from a patient.
  • the expression level of a biomarker is generally measured by comparing its expression level to the expression level of one or several housekeeping genes in a sample for normalisation.
  • the sample from the patient is designated as COPD positive if the expression level of the biomarker exceeds the expression level of the same biomarker in an appropriate control (for example a healthy tissue) by a set threshold value. In some cases, it may be downregulated and the control may be higher.
  • RNA can also be analysed for example by northern blot, next generation sequencing or after amplification by using spectrometric techniques that include measuring the absorbance at 260 and 280 nm.
  • the term "amplified”, when applied to a nucleic acid sequence, refers to a process whereby one or more copies of a particular nucleic acid sequence is generated from a nucleic acid template sequence, preferably by the method of polymerase chain reaction.
  • Other methods of amplification include, but are not limited to, ligase chain reaction (LCR), polynucleotide-specific based amplification (NSBA), or any other method known in the art.
  • correlating refers to comparing the presence or amount of the marker(s) in a sample from a patient to its presence or expression level in a sample from a person known to suffer from, or is at risk of suffering from, a given condition.
  • a marker expression level in a patient sample can be compared to a level known to be associated with a specific diagnosis.
  • diagnosis refers to the identification of the disease, in this case COPD, at any stage of its development, and also includes the determination of predisposition of a su bject to develop the disease.
  • splice variant refers to the product of an alternative splicing event.
  • Alternative splicing events include exon skipping or inclusion, alternative 5' or 3' splice site usage, or intron retention.
  • fluorescent dye refers to any chemical that absorbs light energy of a specific wavelength and re-emits light at a different wavelength.
  • Fluorescent dyes suitable for labelling nucleic acids include for example FAM (5-or 6-carboxyfluorescein), VIC, N ED, Fluorescein, FITC, I D-700/800, CY3, CY5, CY3.5, CY5.5, H EX, TET, TAMRA, JOE, ROX, BODI PY TM R, Oregon Green, Rhodamine Green, Rhodamine Red, Texas Red, Yakima Yellow, Alexa Fluor, PET and the like.
  • isolated when used in reference to a nucleic acid means that a naturally occurring sequence has been removed from its normal cellular (e.g. chromosomal) environment or is synthesised in a non-natural environment (e.g. artificially synthesised). Thus, an "isolated" sequence may be in a cell-free solution or placed in a different cellular environment.
  • kits are packaged combinations optionally including instructions for use of the combination and/or other reactions and components for such use. If the kit contains nucleic acids, the kit may also comprise synthetic or non-natural variants of said nucleic acids.
  • a synthetic or non- natural nucleic acid is to be understood as a nucleic acid comprising any chemical, biochemical or biological modification, such that the nucleic acid does not appear in nature in this form. Such modifications include, but are not limited to, labelling with a fluorescent dye or a quencher moiety, a biotin tag, as well as modification(s) in the backbone of a nucleic acid, or any other modification that distinguishes the nucleic acid from its natural counterpart. The same applies also to other natural compounds such as proteins, lipids and the like.
  • patient refers to a living human or non-human organism that is receiving medical care or that should receive medical care due to a disease, or is suspected of having a disease. This includes persons with no defined illness who are being investigated for signs of pathology. Thus, the methods and assays described herein are applicable to both, human and veterinary disease.
  • primer refers to a nucleic acid, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH.
  • the primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used.
  • primers have a length of from about 15-100 bases, more preferably about 20-50, most preferably about 20-40 bases.
  • the primer can be a synthetic element, in the sense that it comprises a chemical, biochemical or biological modification. Such modifications include, but are not limited to, labelling with a fluorescent dye or a quencher moiety, or a modification in the backbone of a nucleic acid, or any other modification that distinguishes the primer from its natural nucleic acid counterpart.
  • probe refers to any element that can be used to specifically detect a biological entity, such as a nucleic acid, a protein or a lipid.
  • the probe also comprises at least one modification that allows its detection in an assay.
  • modifications include, but are not limited to labels such as fluorescent dyes, a specifically introduced radioactive element, or a biotin tag.
  • the probe can also comprise a modification in its structure, such as a locked nucleic acid.
  • fragment refers to, e.g. a splice variant or another shorter form of the m NA transcript.
  • a gene may result in different mRNA forms. These are encompassed by the term fragment.
  • the invention relates to a method for the diagnosis of COPD, risk stratification, disease outcome, disease prognosis or differential severity analysis of COPD in a subject that has or is suspected to have COPD, comprising the steps of, in a sample of said subject: (a) determining the level of one or more transcripts according to SEQ ID NO. 75 to SEQ ID NO. 233 or fragments thereof in a sample taken from said subject, wherein the level of one or more transcripts according to SEQ ID NO. 75 to SEQ ID NO.
  • 233 or fragments thereof is correlated with the diagnosis of COPD, a defined risk stratification, a defined disease outcome, a defined disease prognosis, or a differential severity of COPD in a subject, wherein said diagnosis of COPD, defined risk stratification, defined disease outcome, defined disease prognosis, or a differential severity of COPD in a subject is given if the level of one or more transcripts according to SEQ ID NO. 75 to SEQ ID NO. 233 or fragments thereof is above or below a certain cut-off value.
  • the method according to the invention also involves comparing the level of marker for the individual/patient/subject to diagnosed with a predetermined value.
  • the predetermined value can take a variety of forms. It can be single cut-off value. This can be for instance a median or mean or the 75 th , 90 th , 95 th or 99 th percentile of a reference population. This can be for instance also an "optimal" cut-off value.
  • the optimal cut-off value for a given marker is the value where the product of diagnostic sensitivity and specificity is maximal for this marker.
  • the predetermined value can be established based upon comparative groups, such as where the risk in one defined group is double the risk in another defined group. It can be a range, for example, where the tested population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group and a high-risk group, or into quartiles, the lowest quartile being individuals with the lowest risk and the highest quartile being individuals with the highest risk.
  • the predetermined value can vary among particular reference populations selected, depending on their habits, ethnicity, genetics, sex etc. Accordingly, the predetermined values selected may take into account the category in which individual falls. Appropriate ranges and categories can be selected with no more than routine experimentation by those of ordinary skill in the art.
  • particular thresholds for one or more markers in a panel are not relied upon to determine if a profile of marker levels obtained from a subject are indicative of a particular diagnosis/prognosis. Rather, the present invention may utilize an evaluation of a marker panel "profile" as a unitary whole.
  • a particular "fingerprint" pattern of changes in such a panel of markers may, in effect, act as a specific diagnostic or prognostic indicator. As discussed herein, that pattern of changes may be obtained from a single sample, or from temporal changes in one or more members of the panel (or a panel response value).
  • a panel herein refers to a set of markers.
  • a panel response value can be derived by various methods.
  • Cox proportional hazards analysis Another example is optimizing ROC curves: This can be achieved by plotting ROC curves for the sensitivity of a particular panel of markers versus l-(specificity) for the panel at various cut-offs.
  • a profile of marker measurements from a subject is considered together to provide a global probability (expressed either as a numeric score or as a percentage risk) of a diagnosis or prognosis.
  • an increase in a certain subset of markers may be sufficient to indicate a particular diagnosis/prognosis in one patient, while an increase in a different subset of markers may be sufficient to indicate the same or a different diagnosis/prognosis in another patient.
  • Weighting factors may also be applied to one or more markers in a panel, for example, when a marker is of particularly high utility in identifying a particular diagnosis/prognosis, it may be weighted so that at a given level it alone is sufficient to signal a positive result.
  • a weighting factor may provide that no given level of a particular marker is sufficient to signal a positive result, but only signals a result when another marker also contributes to the analysis.
  • the invention also relates to a method for the diagnosis of COPD, in a subject that has or is suspected to have COPD, comprising the steps of, in a sample of said subject:
  • Transcripts with SEQ I D NO. 75 to SEQ I D NO. 158 have been shown to be particularly useful in diagnosis. Up- and down regulation is as follows. For all biomarkers of probes SEQ I D NO. 1 to SEQ I D NO. 35 the respective expression is significant if these are up-regulated.
  • Diagnostic sensitivity is the relative fraction of patients, carrying the disease or the risk for developing the disease (depending on the diagnostic or prognostic question to be answered in any particular case), which are correctly recognized as such by a marker ("true positives")
  • the diagnostic specificity is the relative fraction of patients, not carrying the disease or the risk for developing the disease (depending on the diagnostic or prognostic question to be answered in any particular case), which are recognized as such by a marker ("true negatives").
  • This can by a cut-off value optimized for a maximal negative predictive value or maximal positive predictive value, depending on clinical or economical needs. Thereby optimizing specificity and sensitivity.
  • the invention preferably concerns a method wherein the level of one or more transcripts according to SEQ ID NO. 75 to SEQ ID NO. 233 or fragments thereof is preferably correlated with the said diagnosis of COPD, defined risk stratification, defined disease outcome, defined disease prognosis or a differential severity of COPD in a subject by a method which is selected from the following alternatives: correlation with respect to the median of the level in an ensemble of predetermined samples,
  • correlation with a mathematical model, such as for example Cox Regression.
  • markers and/or marker panels are selected to exhibit at least about 70% sensitivity, more preferably at least about 80% sensitivity, even more preferably at least about 85% sensitivity, still more preferably at least about 90% sensitivity, and most preferably at least about 95% sensitivity, combined with at least about 70% specificity, more preferably at least about 80% specificity, even more preferably at least about 85% specificity, still more preferably at least about 90% specificity, and most preferably at least about 95% specificity.
  • both the sensitivity and specificity are at least about 75%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95%.
  • a positive likelihood ratio, negative likelihood ratio, odds ratio, or hazard ratio is used as a measure of a test's ability to predict risk or diagnose a disease.
  • a positive likelihood ratio a value of 1 indicates that a positive result is equally likely among subjects in both the "diseased" and "control" groups; a value greater than 1 indicates that a positive result is more likely in the diseased group; and a value less than 1 indicates that a positive result is more likely in the control group.
  • markers and/or marker panels are preferably selected to exhibit a positive or negative likelihood ratio of at least about 1.5 or more or about 0.67 or less, more preferably at least about 2 or more or about 0.5 or less, still more preferably at least about 5 or more or about 0.2 or less, even more preferably at least about 10 or more or about 0.1 or less, and most prefera bly at least about 20 or more or about 0.05 or less.
  • the term "about” in this context refers to +/- 5% of a given measurement.
  • markers and/or marker panels are preferably selected to exhibit an odds ratio of at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less.
  • a value of 1 indicates that the relative risk of an endpoint (e.g., death) is equal in both the "diseased" and “control” groups; a value greater than 1 indicates that the risk is greater in the diseased group; and a value less than 1 indicates that the risk is greater in the control group.
  • markers and/or marker panels are preferably selected to exhibit a hazard ratio of at least about 1.1 or more or about 0.91 or less, more preferably at least about 1.25 or more or a bout 0.8 or less, still more preferably at least about 1.5 or more or about 0.67 or less, even more preferably at least about 2 or more or about 0.5 or less, and most prefera bly at least about 2.5 or more or a bout 0.4 or less.
  • the term "about” in this context refers to +/5% of a given measurement.
  • associating a diagnostic or prognostic indicator, with a diagnosis or with a prognostic risk of a future clinical outcome is a statistical analysis.
  • a marker level of greater than X may signal that a patient is more likely to suffer from an adverse outcome than patients with a level less than or equal to X, as determined by a level of statistical significance.
  • a change in marker concentration from baseline levels may be reflective of patient prognosis, and the degree of change in marker level may be related to the severity of adverse events.
  • Statistical significance is often determined by comparing two or more populations, and determining a confidence interval and/or a p value.
  • Preferred confidence intervals of the invention are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while preferred p values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001.
  • the cut-off value of the level of one or more transcripts according to SEQ I D NO. 75 to SEQ ID NO. 233 or fragments thereof is about 1.5 fold ( ⁇ 20%), 2 fold ( ⁇ 20%), 3 fold ( ⁇ 20%), 4 fold ( ⁇ 20%) and most preferably 5 fold ( ⁇ 20%) or more, higher than (or lower than) the amount of the control sample, and may deviate depending on the patient analysed by about 5%, 8%, 10%, or 20%.
  • the invention also relates to a method according to any of the preceding claims comprising the steps of
  • the invention also relates to a method for determining the differential severity of COPD in a subject according any of the preceding claims, wherein the subject is under a COPD condition selected from the group of
  • multiple determinations of diagnostic or prognostic markers can be made, and a temporal change in the marker can be used to determine a diagnosis or prognosis.
  • a marker concentration in a subject sample may be determined at an initial time, and again at a second time from a second subject sample.
  • an increase in the marker from the initial time to the second time may be indicative of a particular diagnosis, or a particular prognosis.
  • a decrease in the marker from the initial time to the second time may be indicative of a particular diagnosis, or a particular prognosis.
  • the invention is thus also suited for a method of medical decision making for individual patient therapy related to the severity of the COPD disease by monitoring therapy response to a certain drug in a subject with sepsis or a sepsis like disease, comprising the steps of (a) - (c):
  • COPD may need to be differentiated from other causes of shortness of breath such as congestive heart failure, pulmonary embolism, pneumonia or pneumothorax. Many people with COPD mistakenly think they have asthma. The distinction between asthma and COPD is made on the basis of the symptoms, smoking history, and whether airflow limitation is reversible with bronchodilators at spirometry. Tuberculosis may also present with a chronic cough and should be considered in locations where it is common. Less common conditions that may present similarly include bronchopulmonary dysplasia and obliterative bronchiolitis. Chronic bronchitis may occur with normal airflow and in this situation it is not classified as COPD. The present invention is able to differentially diagnose COPD and the other causes, congestive heart failure, pulmonary embolism, pneumonia, pneumothorax, asthma, tuberculosis, bronchopulmonary dysplasia and chronic bronchitis.
  • the invention relates very preferably to the following uses and methods:
  • the invention relates to a method for differentially diagnosing between COPD and another disease in a subject, wherein the disease is either COPD or alternatively another disease selected from the group comprising (i) congestive heart failure, (ii) pulmonary embolism, (iii) pneumonia, (iii) pneumothorax, (iv) asthma, tuberculosis, (v) bronchopulmonary dysplasia and (vi) chronic bronchitis, comprising the steps of:
  • the sample is selected from a group comprising: a plasma sample, a serum sample, a whole blood sample, a blood sample or fractions thereof, a lymphatic fluid sample, a urine sample, a lung tissue, sputum, saliva, biopsy material, lymph nodes, urine, ejaculate, blood, blood serum, blood plasma, circulating tumour cells in blood or lymph, exosomes, micro vesicles, blood cells, leukocytes, monocytes, lymphocytes and neutrophils.
  • sample refers also to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, or evaluation of a subject of interest, such as a patient.
  • test samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions.
  • test samples would be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.
  • said sample is an isolated fraction of monocytes.
  • the sample is also preferably sputum.
  • the invention relates to a method of risk stratification in COPD encompassing determining whether the patient has an inflammation of the lung comprising inflammatory granulocytes, such as eosinophils and/or neutrophils comprising: (a) determining the level of one or more transcripts according to SEQ ID NO. 159 to SEQ ID NO.
  • the level may also be below the cut-off. This depends on the marker.
  • the method/therapy may be further adapted in so far as the inflammation is concerned. Then anti- inflammation drugs are given.
  • the invention relates to a primer or probe nucleic acid or equivalent thereto that hybridizes under stringent conditions to a transcript or fragment of a nucleic acid transcript with a SEQ ID NO. 75 to SEQ ID NO. 233.
  • the primer or probe is selected from the group of SEQ ID NO. 1 to 74.
  • the primer or probe may be any other probe as long as it specifically binds SEQ ID NO. 75 to SEQ ID NO. 233 under stringent conditions.
  • the primer or probe is labelled.
  • the invention also relates to uses of the primers and probes and transcripts in the methods of the invention.
  • CAAAC CA AGCACA CC CCAGT ACA GGCAGAAGAGGGAGGGAGGGAGGGCCAAAAA
  • a nucleic acid with a SEQ I D NO. 75 to SEQ ID NO. 233 for the diagnosis of COPD, risk stratification, disease outcome, disease prognosis, or differential severity analysis of COPD in a subject that has or is suspected to have COPD.
  • the SEQ I D NO. 1 to 74 are probes and are as such anti-sense to their respective transcripts.
  • a claim herein refers to, e.g. a method for the diagnosis of COPD, risk stratification, disease outcome, disease prognosis, or differential severity analysis of COPD in a subject that has or is suspected to have COPD, comprising the steps of, in a sample of said subject: (a) determining the level of one or more transcripts according to SEQ ID NO. 75 to SEQ I D NO. 233 or fragments thereof in a sample taken from said subject, (b) wherein the level of one or more transcripts according to SEQ I D NO. 75 to SEQ I D NO.
  • 233 or fragments thereof is correlated with the diagnosis of COPD, a defined risk stratification, a defined disease outcome, a defined disease prognosis, or a differential severity of COPD in a subject wherein, (c) said diagnosis of COPD, defined risk stratification, defined disease outcome, defined disease prognosis, or a differential severity of COPD in a subject is given if the level of one or more transcripts according to SEQ I D NO. 75 to SEQ ID NO. 233 or fragments thereof is above or below a certain cut-off value, then this applies also to the reverse complement of the SEQ ID given above.
  • All SEQ I D NOs. include also the reverse complements thereof, as in some cases the sequences given herein are the m NA sequence and in other cases the cDNA sequences.
  • Figures 1 to 74 show the plotting of ROC curves for the sensitivity of a particular panel of markers versus l-(specificity) for the panel at various cut-offs. Those markers are preferred that show very good values. They will not all be designated here as this is evident from the ROC curves.
  • Diagnosis of COPD a linear, additive, multivariate model, which is used with covariates: type: COPD, healthy; smoker: yes, no; gender: male, female.
  • Diagnosis of inflammation and type (neutrophilic or eosinophilic): a linear, additive, multivariate model was applied using covariates: type: inflammation, no inflammation, neutrophilic, eosinophilic; smoker: yes, no; gender: male, female.
  • the markers from the monocytes can predict the inflammation status of the lung and the type of inflammation in the lung.
  • Diagnosis of COPD a linear, additive, multivariate model, with applied covariates: type: control GOLD l-IV; smoker: yes, no; gender: male, female.
  • transcriptomes of sputum and blood samples were analysed by DNA microarrays. From blood, analyses were done in RNAs derived from whole-blood samples as well as from isolated lymphocytes, granulocytes, and monocytes.
  • Patients and controls consisted of 150 subjects of both genders aged 40 to 75 years with a smoking history of >10 pack years (smokers only) and evidence (COPD patients) or absence (healthy controls) of airway obstruction (FEV1/FVC ⁇ 70%).
  • RNA samples were collected in PAXgene RNA tubes (Preanalytix) and cryo-preserved at -80°C.
  • PAXgene RNA tubes Preanalytix
  • granulocytes and monocytes from whole blood the pluriBead cell separation system (pluriSelect) was used.
  • Separated blood cells were lysed in 1ml Qiazol (Qiagen) and stored at -80°C. Beside whole blood and separated blood cells, sputum samples were collected and stored in 1ml Qiazol at -80°C.
  • RNA including miRNA was isolated using the PAXgene miRNA Kit (for whole blood samples) and the miRNeasy Mini Kit (for blood cells and sputum samples) on the QIAcube instrument (all from Qiagen), respectively. Subsequent manual DNase I (Turbo DNA free kit, Life Technologies) digestion was performed to obtain DNA-free RNA samples. RNA concentration was further determined using a Nanodrop 1000 (Peqla b). RNA integrity was verified on an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA), and only RNA samples with an RNA-lntegrity-Number (RIN) of at least 6 were further processed. Biomarker screening by microarrays
  • microarray screening was performed using microarrays with 8 x 60 000 probes (Agilent SurePrint G3 Human Gene Expression v3 8x60K Microarray Kit). Whole blood, blood cell and sputum samples, each 40, of the prospective COPD cohort were analysed. Using the Quick Amp Labeling Kit (Agilent) cRNA was synthesized from 200 ng total RNA, and 600 ng cRNA was hybridized on the arrays (Agilent Gene Expression Hybridization Kit).
  • RNAs from isolated monocytes carried RNA biomarkers that discriminated COPD from controls almost as well as RNAs from sputum.
  • Lymphocyte RNA patterns were also discriminative, yet yielded lower sensitivity and specificity values than monocyte and sputum RNAs. Furthermore, patterns from both, sputum and monocytes correlated with the progress of COPD, as defined by the clinical GOLD standard.
  • RNA biomarker patterns in blood monocytes with high specificity and sensitivity.

Abstract

L'invention concerne une méthode pour le diagnostic de la BPCO, la stratification des risques, l'issue pathologique, le pronostic de la maladie ou l'analyse de la sévérité différentielle de la BPCO chez un sujet ayant ou suspecté d'avoir une BPCO, la méthode comprenant les étapes consistant à : (a) déterminer le niveau d'un ou de plusieurs transcrits selon SEQ ID No: 75 à SEQ ID No: 233 ou des fragments de celles-ci dans un échantillon prélevé sur ledit sujet, et (b) à mettre le niveau du ou des transcrits selon SEQ ID No: 75 à SEQ ID No: 233 ou des fragments de celles-ci en corrélation avec le diagnostic de la BPCO, une stratification des risques définie, une issue pathologique définie, un pronostic de la maladie défini, ou une sévérité différentielle de la BPCO chez le sujet, ledit diagnostic de la BPCO, ladite stratification des risques définie, ladite issue pathologique définie, ledit pronostic de la maladie défini, ou ladite sévérité différentielle de la broncho-pneumopathie chronique obstructive chez le sujet étant avéré si le niveau du ou des transcrits selon SEQ ID No: 75 à SEQ ID No: 233 ou des fragments de celles-ci est supérieur ou inférieur à une certaine valeur de coupure.
PCT/EP2017/056362 2016-03-17 2017-03-17 Diagnostic de la broncho-pneumopathie chronique obstructive (bpco) WO2017158152A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16160877 2016-03-17
EPEP16160877.3 2016-03-17

Publications (1)

Publication Number Publication Date
WO2017158152A1 true WO2017158152A1 (fr) 2017-09-21

Family

ID=55587132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/056362 WO2017158152A1 (fr) 2016-03-17 2017-03-17 Diagnostic de la broncho-pneumopathie chronique obstructive (bpco)

Country Status (1)

Country Link
WO (1) WO2017158152A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110503158A (zh) * 2019-08-28 2019-11-26 山东健康医疗大数据有限公司 一种基于时间因素的药物疾病相关性分析方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105252A2 (fr) * 2005-03-28 2006-10-05 The Regents Of The University Of Colorado Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
WO2010129860A2 (fr) * 2009-05-08 2010-11-11 The Ohio State University Research Foundation Profil d'expression et ciblage de micro-arn dans un tissu pulmonaire atteint d'une bronchopneumopathie chronique obstructive (bpco) et leurs méthodes d'utilisation
WO2014186036A1 (fr) * 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
WO2015185658A2 (fr) * 2014-06-05 2015-12-10 Medizinische Universität Wien Méthodes de diagnostic de la bronchopneumopathie chronique obstructive (bpco) à l'aide de nouveaux biomarqueurs moléculaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105252A2 (fr) * 2005-03-28 2006-10-05 The Regents Of The University Of Colorado Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
WO2010129860A2 (fr) * 2009-05-08 2010-11-11 The Ohio State University Research Foundation Profil d'expression et ciblage de micro-arn dans un tissu pulmonaire atteint d'une bronchopneumopathie chronique obstructive (bpco) et leurs méthodes d'utilisation
WO2014186036A1 (fr) * 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
WO2015185658A2 (fr) * 2014-06-05 2015-12-10 Medizinische Universität Wien Méthodes de diagnostic de la bronchopneumopathie chronique obstructive (bpco) à l'aide de nouveaux biomarqueurs moléculaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Agilent Technologies", 4 January 2016, article AG: "Agilent Technologies", XP055379911 *
DOWDY; WEARDEN: "Statistics for Research", 1983, JOHN WILEY & SONS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110503158A (zh) * 2019-08-28 2019-11-26 山东健康医疗大数据有限公司 一种基于时间因素的药物疾病相关性分析方法

Similar Documents

Publication Publication Date Title
JP7297015B2 (ja) エピジェネティックな染色体相互作用
US8765371B2 (en) Method for the in vitro detection and differentiation of pathophysiological conditions
CN105143467B (zh) 用于预测间质性肺炎的风险的方法
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
US20130143752A1 (en) Gene biomarkers of lung function
US10584383B2 (en) Mitochondrial non-coding RNAs for predicting disease progression in heart failure and myocardial infarction patients
CN113502326B (zh) 基于生物标志物的肺动脉高压的诊断产品及其应用
WO2018146162A1 (fr) Biomarqueur moléculaire pour le pronostic de patients atteints de septicémie
JP2023157965A (ja) アトピー性皮膚炎の検出方法
WO2017158152A1 (fr) Diagnostic de la broncho-pneumopathie chronique obstructive (bpco)
JP7392224B2 (ja) びまん性肺胞傷害型薬剤性間質性肺炎のｍｉＲＮＡ診断バイオマーカー
US20210087634A1 (en) Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna
US20120264633A1 (en) Methods for detecting thrombocytosis using biomarkers
US20200232031A1 (en) Method of diagnosing and treating acute rejection in kidney transplant patients
US10066270B2 (en) Methods and kits used in classifying adrenocortical carcinoma
CN114839369B (zh) 急性高原反应微生物标志物及其应用
WO2023246808A1 (fr) Utilisation d'exons courts associés au cancer pour faciliter le diagnostic et le pronostic du cancer
WO2017158146A1 (fr) Procédé de diagnostic de maladies chroniques basé sur une analyse de transcriptome de monocytes
EP2607494A1 (fr) Biomarqueurs pour l'évaluation du risque de cancer des poumons
CN116254335A (zh) Adam12生物标志物在冠状动脉扩张症诊断中的应用
CN116536412A (zh) 生物标记物pglyrp2及其试剂盒的应用
CN117660643A (zh) 生物标志物在检测个体的hrd状态中的应用
WO2020188564A1 (fr) Méthodes de pronostic et de traitement du cancer de la prostate
CN116144764A (zh) 一种检测青光眼的产品
JP2006101789A (ja) 高血圧症のリスクの評価方法

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17716138

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17716138

Country of ref document: EP

Kind code of ref document: A1